S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with
or without vemurafenib works in treating patients with colorectal cancer that has spread to
nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be
removed by surgery. Irinotecan hydrochloride and vemurafenib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known
whether irinotecan hydrochloride and cetuximab are more effective with or without vemurafenib
in treating colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Genentech/Roche National Cancer Institute (NCI) Roche-Genentech